Small Caps - USA’s Post

AI and transcriptomics identify dual targets for ageing and cancer #research #lifesciences #healthcare #agingresearch #cancerresearch #oncologyresearch #cancer #oncology #artificialintelligence #machinelearning #discoveryresearch

#AI models developed by GE HealthCare and Vanderbilt University Medical Center (VUMC) were able to predict patient responses to #cancer #immunotherapies with 70% to 80% accuracy, according to study findings published in the Journal of Clinical Oncology Clinical Cancer Informatics. https://lnkd.in/dG27DbwG #artificialintelligence #clinicalresearch #GEHealthCare #immunotherapy #medicalaffairs #oncology #VanderbiltUniversity

Pretty chuffed to finally get this review article out there. Highlights just one of the ways that nanomedicines can be utilised to improve clinical efficacy of cancer treatments. https://lnkd.in/gUaTYPxP

I am happy to share our latest research on the revelation of CNV-associated lncRNA signatures in Prostate Cancer and their prognostic implications through a comprehensive multi-omics analysis. #PRAD #Multi-omics #Prognosticbiomarkers https://lnkd.in/d-Ki33wj

MRD clearance as a primary endpoint: DECIPHER is a HER2 directed ADC study for gastroesophageal cancer in the adjuvant setting where Signatera will guide patient selection and ctDNA clearance is the primary end point.

If you are interested in new immunotherapy targets in cancer patients, and how the may relate to survival, you should read this study, carried out on more than 15thousand patients https://lnkd.in/dyywWujQ

First patient sucessfully dosed with Lu177-SN201. The open phase 1/2a study aims to generate important data on safety, biodistribution, and early efficacy in patients with cancer. #radiopharmaceuticals #cancertreatment #cancer #clinicaltrial https://lnkd.in/dDQeyYt6

Bayer to present new prostate cancer data https://lnkd.in/eMPpDXxb #MetastaticProstateCancer #AdvancedCancer #ifcancerspreads #septemberisprostatecancerawarenessmonth #prostatecancer #ResearchSavesLives

Limited efficacy and resistance pose challenges in treating advanced prostate cancer, emphasizing the need for targeted therapies with alternative mechanisms of action. However, identifying such targets from millions of publications across multiple data sources is challenging. Using Causaly Cloud, we extracted relevant targets for prostate cancer from comprehensive data sources in just seconds: https://hubs.la/Q02b01h20 #TargetDiscovery #ProstateCancer #AI

Activation of RYR2 in T-cells reduces the effectiveness of PD-1 immunotherapies in cancer. Knockdown of RyR2 or inhibition of AKT in CD8+ T cells maintained TCF1 levels, induced a sustained anti-tumor response, and enhanced responsiveness to anti-PD1 therapy.  https://lnkd.in/e6CdPMw9